TO THE EDITOR
The role of HCV as a possible cause in the pathogenesis of lymphoproliferative disorders was prompted by the observations made on essential mixed cryoglobulinemia considered by some investigators to be a variant of low-grade B cell non-Hodgkin lymphoma (NHL). HCV RNA and antibodies to HCV (anti-HCV) have been found in up to 98% of patients with mixed cryoglobulinemia, and approximately 36% of patients with chronic HCV infection have mixed cryoglobulinemia. Regression of B cell expansion in HCV patients affected by cryoglobulinemia has also been reported in patients responsive to interferon therapy. 1 It has also been demonstrated that HCV is both a hepatotrophic and a lymphotrophic virus, and that the persistence of HCV stimulation in these cells may chronically cause a clonal expansion eventually resulting in malignant B cell lymphoproliferative diseases. Several Italian studies, 1 and more recently studies from North America 2 have postulated a direct relationship between HCV infection and the development of these tumors. The overall prevalence of HCV evaluated in 2274 B cell non Hodgkin lymphoma patients reviewed by Silvestri, is 19.1%, and in almost half of those analysed an association with the production of cryoglobulins was present.
2 Unfortunately, data from the United Kingdom, 3 and more recently from Canada 4 and France, 5 did not confirm this hypothesis. We determined prospectively the prevalence of HCV infection in patients with B cell lymphoproliferative diseases in a very homogeneous geographical population of Southern Italy where the prevalence of this infection is particularly elevated. The prevalence of hepatitis B infection and cryoglobulinemia were also investigated. Between September 1999 and October 2001, 60 consecutive patients (32 females and 28 males; median age 65 years, range 25-88 years) with B cell lymphoproliferative diseases (55 non-Hodgkin lymphoma and five multiple myeloma) were evaluated at the Division of Medical Oncology of the Oncology Institute of Bari (Italy). Over the same time period, 63 control patients with non-hematological malignancies were recruited from the Surgery Department of the same Institute. Patients were similar in the two groups studied with respect to age, sex, ethnicity; the prevalence of risk factors for HCV infection was slightly higher in the lymphoma group with respect to the control group. All patients were heterosexual, Caucasian and Italian-born. Details of risk factors for the acquisition of hepatitis C, including intravenous drug use, blood transfusions, surgical procedures, body piercing, tattoos and demographic characteristics were obtained from a questionnaire. Patients were also examined for signs of liver chronic disease. The diagnosis of lymphoproliferative diseases was determined in all cases on the basis of the histological analysis of a lymph node or extranodal tissues and bone marrow biopsy using the histological modified Working Formulation classification. Immunophenotypic analysis for surface B-and T-lymphocytic markers was also performed. Serological test included the study of the markers for HCV infection (antibodies HCV and HCV-RNA) and HBV infection (antibodies to hepatitis B surface antigen, hepatitis B surface antigen, antibodies hepatitis B core antigen, hepatitis B-e-antigen, antibody to hepatitis B-e-antigen). All markers of the hepatitis B virus and anti-HCV detected were tested with a third-generation microparticle enzyme immunoassay (MEIA). HCV-RNA detection was performed by a reverse-trascription polymerase chain reaction (RT-PCR) assay. HCV, HCV RNA and cryoglobulinemia in the two groups are shown in Table 1 .
Both HCV RNA and anti-HCV were detected simultaneously in all of the 12 positive patients of the B cell lymphoproliferative group. Also the patients in the control group who were positive for HCV RNA, had detectable levels of anti-HCV antibodies. Regarding B hepatitis, four of the 12 HCV-positive patients were also positive for AntiHBc antibody and two of them were positive for AntiHBs too; AntiHBe was negative in all patients, whereas only one patient was positive for HBsAg. Chronic liver disease had been diagnosed only in one HCV-positive patient with high grade B cell lymphoma (8.3%). None of control group showed alteration of liver function. At least one risk factor for HCV exposure was identified in 27 patients of B cell lymphoma group (one risk in 24 patients, two risks in three patients); in the control group only 17 of 63 patients had one risk factor. Seven of 12 HCV-positive patients (58.3%) with B cell nonHodgkin lymphoma had one risk factor for HCV exposure. The prevalence of HCV infection in the different histopathological NHL groups is shown in Table 2 .
With regard to the presence of cryoglobulins, only two cases (one low grade lymphoma and one MALT lymphoma) were found positive (3.3%) in the absence of any clinical signs of mixed cryoglobulinemia. These patients were also found to be positive for anti-HCV antibodies and HCV-RNA. The low-grade lymphoma patient was also positive for HbsAg and HbcAg, but he was not in the active phase of viral replication because serum HBV-DNA was absent. No liver function alteration was associated in either patient.
We show that the incidence of HCV infection among patients with B cell lymphoma was not significantly higher than that in the control The level of cryoglobulinemia was expressed as a percentage. group. Our results contrast with the findings from southern Europe and part of North America. To our knowledge, our study is the first one from Italy that reports a negative correlation between B cell lymphoma and the prevalence of HCV infection. In particular, although the prevalence in our group of non-Hodgkin lymphoma patients was similar to that of other Italian studies, the prevalence of HCV infection in our control group was higher (14.2%) than that reported in other control groups from northern Italy (3.1%) or healthy blood donors (2.87%) from the same geographical area of northeast Italy. 6 Nevertheless, a large study in a community-based survey in southern Italy has recently reported the prevalence distribution of HCV infection of the general population. Among 1352 subjects enrolled, 195 (14.4%) tested reactive to antibody to HCV with enzyme immunoassay (EIA3). 7 These results are very similar to those reported in our control group in which geographic characteristics and risk factors for HCV infection were identical to those reported in the general population from the same geographical area. Moreover, in our study, the prevalence of risk factors for HCV infection was slightly higher in the lymphoma group. This may be one of the reasons for the higher prevalence of HCV infection reported in our lymphoma group with respect to the control group.
The contrasting findings of our data with respect to those from northern Italy may depend on the very different prevalence of HCV infection in the general population in which the hyperendemicity of HCV infection epidemiology is evident. An alternative, weak reason may be related to the different histological subtypes of lymphoma enrolled in the study. In fact, it is known that low-grade lymphomas are much more likely to be associated with the HCV infection. In particular, lymphoplasmacytoid lymphoma/immunocytoma, the most frequent histological type among HCV-related lymphoma (26-49%), occurred more frequently in the studies from Italy.
1 Our HCV-positive cohort had an even distribution of low-, intermediate-, and high-grade lymphoma. However, the quota of patients with high grade lymphoma was very poor. When extranodal disease occurred, the prevalence of HCV infection was not different from that of nodal lymphoma (23% of MALT lymphoma vs 21% of nodal lymphoma). The absence of a link between HCV infection and gastric MALT lymphoma has been recently confirmed by Tkoub et al 8 in a large, well-characterized series of patients affected by this type of lymphoma.
The strong association between HCV, symptomatic cryoglobulinemia and low-grade lymphoma has been reported by numerous authors. Although asymptomatic cryoglobulinemia has been detected in up to 50% of HCV-infected patients, symptomatic cryoglobulinemia is rare in patients who are HCV-positive. In contrast, the majority of patients with symptomatic mixed cryoglobulinemia have HCV infection, and in those who develop low-grade lymphoma the pathogenetic link with the HCV infection is strengthened to the finding of HCV in lymphoma tissue. 1 In our patient population the prevalence of cryoglobulinemia was very low. Only two cases (3.3%) were found to be positive for low levels of cryoglobulins in the absence of any clinical signs. Regarding monoclonal gammopathy, although two studies have shown a high prevalence of HCV infection in patients with benign or malignant monoclonal gammopathy others have not. In conclusion, our findings show a modest increase of prevalence of HCV infection among patients with B cell lymphoproliferative disorders in a very homogeneous population of southern Italy. These data question the role of HCV in the pathogenesis of this neoplasm. Thus, the clonal B cell expansion in patients with chronic HCV infection may be only one of many factors necessary for the full expression of malignant conditions. Moreover, the role of HCV infection perhaps depends on the variability of its pathogenicity according to the viral load and genotype. Other factors including genetic, immunologic, or environmental aspects that can vary widely across geographic regions, are probably involved in the pathogenesis of these disorders. sary for constant replacement of senescent mature cells or to respond to a stress, like hemorrhage or infection. This implies precise regulation of the balance between cell growth, survival and differentiation, regulated mainly by soluble or membrane-bound cytokines.
1 Immature hematopoietic cells are fragile and strictly cytokine-dependent. Macrophage colony-stimulating factor (M-CSF) has been proved to be able to rescue normal hematopoietic progenitors and some myeloid leukemia blasts from death. 2 Recent evidence has indicated that proteins of the inhibitor of apoptosis (IAP) family, whose expression might be under the regulation of NF-B, can block apoptotic events by directly binding and inhibiting selected caspases. A potent mam-
